Andrew E. Aplin

10.8k total citations · 5 hit papers
121 papers, 7.8k citations indexed

About

Andrew E. Aplin is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Andrew E. Aplin has authored 121 papers receiving a total of 7.8k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Molecular Biology, 39 papers in Oncology and 34 papers in Cell Biology. Recurrent topics in Andrew E. Aplin's work include Melanoma and MAPK Pathways (38 papers), Ocular Oncology and Treatments (26 papers) and Cell Adhesion Molecules Research (22 papers). Andrew E. Aplin is often cited by papers focused on Melanoma and MAPK Pathways (38 papers), Ocular Oncology and Treatments (26 papers) and Cell Adhesion Molecules Research (22 papers). Andrew E. Aplin collaborates with scholars based in United States, China and South Korea. Andrew E. Aplin's co-authors include R. L. Juliano, Alan K. Howe, Suresh K. Alahari, Yongping Shao, Dan A. Erkes, Emad S. Alnemri, Ethan V. Abel, Corey Rogers, Teresa Fernandes‐Alnemri and Timothy J. Purwin and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Nature Communications.

In The Last Decade

Andrew E. Aplin

116 papers receiving 7.7k citations

Hit Papers

Signal Transduction and Signal Modulation by Cell Adhesio... 1998 2026 2007 2016 1998 2019 2019 1998 2019 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Signal Transduction and Signal Modulation by Cell Adhesion Receptors: The Role of Integrins, Cadherins, Immunoglobulin-Cell Adhesion Molecules, and Selectins
    1998 658 citations Andrew E. Aplin et al. profile →
  2. Gasdermin pores permeabilize mitochondria to augment caspase-3 activation during apoptosis and inflammasome activation
    2019 619 citations Corey Rogers, Dan A. Erkes et al. profile →
  3. m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade
    2019 565 citations Andrew E. Aplin, Yu‐Ying He et al. profile →
  4. Integrin signaling and cell growth control
    1998 564 citations Andrew E. Aplin et al. profile →
  5. Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis
    2019 341 citations Dan A. Erkes, Weijia Cai et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew E. Aplin United States 47 5.4k 1.9k 1.5k 1.3k 1.2k 121 7.8k
Sara M. Weis United States 31 4.3k 0.8× 1.6k 0.8× 1.0k 0.7× 1.3k 1.0× 932 0.8× 53 7.3k
Andréas Bikfalvi France 52 5.0k 0.9× 1.8k 1.0× 1.5k 1.0× 632 0.5× 998 0.8× 182 8.3k
Douglas C. Dean United States 54 8.4k 1.6× 4.6k 2.4× 1.3k 0.9× 1.0k 0.8× 1.4k 1.1× 107 11.9k
Erik H.J. Danen Netherlands 42 3.4k 0.6× 1.4k 0.8× 2.2k 1.4× 2.0k 1.5× 906 0.7× 120 6.7k
Christophe Klein France 42 2.1k 0.4× 1.6k 0.8× 1.1k 0.7× 1.0k 0.8× 1.4k 1.1× 127 6.1k
John Hood United States 30 4.2k 0.8× 1.1k 0.6× 769 0.5× 1.3k 1.0× 648 0.5× 56 7.2k
Andrius Kazlauskas United States 60 9.8k 1.8× 2.4k 1.3× 2.2k 1.5× 1.1k 0.8× 2.3k 1.9× 188 15.1k
Steven M. Frisch United States 37 7.0k 1.3× 2.5k 1.3× 1.8k 1.2× 1.7k 1.3× 1.3k 1.1× 60 10.1k
Anna Dimberg Sweden 38 4.5k 0.8× 2.2k 1.2× 630 0.4× 471 0.3× 1.7k 1.4× 92 7.8k
Dwayne G. Stupack United States 46 4.4k 0.8× 1.5k 0.8× 1.5k 1.0× 2.3k 1.7× 995 0.8× 109 7.3k

Countries citing papers authored by Andrew E. Aplin

Since Specialization
Citations

This map shows the geographic impact of Andrew E. Aplin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew E. Aplin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew E. Aplin more than expected).

Fields of papers citing papers by Andrew E. Aplin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew E. Aplin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew E. Aplin. The network helps show where Andrew E. Aplin may publish in the future.

Co-authorship network of co-authors of Andrew E. Aplin

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew E. Aplin. A scholar is included among the top collaborators of Andrew E. Aplin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew E. Aplin. Andrew E. Aplin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Caksa, Signe, Nicole A. Wilski, Inna Chervoneva, et al.. (2023). Targeting Upregulated cIAP2 in SOX10-Deficient Drug Tolerant Melanoma. Molecular Cancer Therapeutics. 22(9). 1087–1099. 8 indexed citations
2.
Purwin, Timothy J., Vivian Chua, Anna Han, et al.. (2022). Multi-omics Profiling Shows BAP1 Loss Is Associated with Upregulated Cell Adhesion Molecules in Uveal Melanoma. Molecular Cancer Research. 20(8). 1260–1271. 15 indexed citations
3.
Vernon, Mégane, Nicole A. Wilski, Weijia Cai, et al.. (2022). Raptinal Induces Gasdermin E–Dependent Pyroptosis in Naïve and Therapy-Resistant Melanoma. Molecular Cancer Research. 20(12). 1811–1821. 22 indexed citations
4.
Teh, Jessica L.F., Dan A. Erkes, Phil F. Cheng, et al.. (2020). Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors. Cancer Immunology Research. 8(9). 1114–1121. 13 indexed citations
5.
Sanchez, Ileine M., Timothy J. Purwin, Inna Chervoneva, et al.. (2019). In Vivo ERK1/2 Reporter Predictively Models Response and Resistance to Combined BRAF and MEK Inhibitors in Melanoma. Molecular Cancer Therapeutics. 18(9). 1637–1648. 16 indexed citations
6.
Erkes, Dan A., Weijia Cai, Ileine M. Sanchez, et al.. (2019). Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis. Cancer Discovery. 10(2). 254–269. 341 indexed citations breakdown →
7.
Ambrosini, Grazia, Catherine Do, Benjamin Tycko, et al.. (2019). Inhibition of NF-κB–Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal Melanoma. Cancer Research. 79(9). 2415–2425. 34 indexed citations
8.
Capparelli, Claudia, Timothy J. Purwin, Inna Chervoneva, et al.. (2018). ErbB3 Targeting Enhances the Effects of MEK Inhibitor in Wild-Type BRAF/NRAS Melanoma. Cancer Research. 78(19). 5680–5693. 13 indexed citations
9.
Farias, Eduardo, Timothy J. Purwin, Thomas H. Charpentier, et al.. (2018). Effects of Oncogenic Gαq and Gα11 Inhibition by FR900359 in Uveal Melanoma. Molecular Cancer Research. 17(4). 963–973. 69 indexed citations
10.
Sample, Ashley, Baozhong Zhao, Chunli Wu, et al.. (2017). The Autophagy Receptor Adaptor p62 is Up‐regulated by UVA Radiation in Melanocytes and in Melanoma Cells. Photochemistry and Photobiology. 94(3). 432–437. 24 indexed citations
11.
Cheng, Hanyin, Vivian Chua, Timothy J. Purwin, et al.. (2017). Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma. Molecular Cancer Therapeutics. 16(3). 516–528. 54 indexed citations
12.
Hartsough, Edward J., Curtis H. Kugel, Adam C. Berger, et al.. (2017). Response and Resistance to Paradox-Breaking BRAF Inhibitor in Melanomas In Vivo and Ex Vivo. Molecular Cancer Therapeutics. 17(1). 84–95. 20 indexed citations
13.
Cheng, Hanyin, Mizue Terai, Ken Kageyama, et al.. (2015). Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma. Cancer Research. 75(13). 2737–2748. 53 indexed citations
14.
Kugel, Curtis H., Edward J. Hartsough, Michael A. Davies, Yulius Y. Setiady, & Andrew E. Aplin. (2014). Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor. Cancer Research. 74(15). 4122–4132. 45 indexed citations
15.
Weiss, Michele B., et al.. (2012). TWIST1 Is an ERK1/2 Effector That Promotes Invasion and Regulates MMP-1 Expression in Human Melanoma Cells. Cancer Research. 72(24). 6382–6392. 124 indexed citations
16.
Trimmer, Casey, Diana Whitaker‐Menezes, Gloria Bonuccelli, et al.. (2010). CAV1 Inhibits Metastatic Potential in Melanomas through Suppression of the Integrin/Src/FAK Signaling Pathway. Cancer Research. 70(19). 7489–7499. 53 indexed citations
17.
Abel, Ethan V. & Andrew E. Aplin. (2010). FOXD3 Is a Mutant B-RAF–Regulated Inhibitor of G1-S Progression in Melanoma Cells. Cancer Research. 70(7). 2891–2900. 69 indexed citations
18.
Shao, Yongping & Andrew E. Aplin. (2010). Akt3-Mediated Resistance to Apoptosis in B-RAF–Targeted Melanoma Cells. Cancer Research. 70(16). 6670–6681. 151 indexed citations
19.
Longmate, Whitney, et al.. (2009). Mcl-1 Is Required for Melanoma Cell Resistance to Anoikis. Molecular Cancer Research. 7(4). 549–556. 108 indexed citations
20.
Klein, Richard M. & Andrew E. Aplin. (2009). Rnd3 Regulation of the Actin Cytoskeleton Promotes Melanoma Migration and Invasive Outgrowth in Three Dimensions. Cancer Research. 69(6). 2224–2233. 75 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sara M. Weis Breakdown of academic impact, for papers by Andréas Bikfalvi Breakdown of academic impact, for papers by Douglas C. Dean Breakdown of academic impact, for papers by Erik H.J. Danen Breakdown of academic impact, for papers by Christophe Klein Breakdown of academic impact, for papers by John Hood Breakdown of academic impact, for papers by Andrius Kazlauskas Breakdown of academic impact, for papers by Steven M. Frisch Breakdown of academic impact, for papers by Anna Dimberg Breakdown of academic impact, for papers by Dwayne G. Stupack
Rankless by CCL
2026